klinische pädiatrie
130330
DE
EN
Home
Products
Journals
Books
Book Series
Service
Library Service
Help
Contact
Portal
Klinische Pädiatrie
Full-text search
Full-text search
Author Search
Title Search
DOI Search
Metadata Search
Journal
More About This Journal
Editorial Board
Table of Contents
German National License
Imprint
Media
Authors
Instructions for Authors
Submit a Manuscript
Subscription
Subscription Information & Contacts
Institutional Licensing
Job Board
Job Opportunities
PharmaMarket
PharmaMarket
Not Logged In
Login
Username or e-mail address:
Password:
Forgot Access Data?
Register Now
OpenAthens/Shibboleth Login
Shopping Cart
Year (Archive)
2024
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
1980
Issues
Current Issue
Free Sample Issue (01/2024)
Related Books
Pädiatrie
XXVI. Jahrestagung der Kind-Philipp-Stiftung für Leukämieforschung
Abstracts (HTML)
List of Authors
A
B
C
D
E
F
G
H
J
K
L
M
N
O
P
R
S
T
V
W
Z
Ü
Mahlow, E
NTRK1/TrkA expression is a potential regulator of neuroblastoma cross-talk with the schwannian stroma
Makaryan, V
The Association of Mutations in RUNX1 and CSF3R with the Development of Leukemia in Severe Congenital Neutropenia: A unique pathway in leukemogenesis
Maroz, A
Finding the molecular basis for developmental-stage specific differences in hematopoietic stem and progenitor cells
Marschalek, R
Establishing novel test systems to functionally analyze direct and reciprocal MLL fusion proteins
An alternative splice process renders MLL either into an transcriptional activator or repressor
The MLL recombinome 2013: an update
Martinez, N
Relevance of RUNX1/ETO for Leukaemic Propagation in vivo
Mazitschek, R
Dysregulated expression of histone deacetylases in medulloblastoma – potential targets for selective inhibitor treatment
Meyer, C
The MLL recombinome 2013: an update
Milde, T
Selective inhibition of Histone Deacetylase 8 as a novel therapeutic strategy for the treatment of high-risk neuroblastoma
GRHL1 inhibits tumorigenicity and is a prognostic marker in neuroblastoma
Dysregulated expression of histone deacetylases in medulloblastoma – potential targets for selective inhibitor treatment
Möricke, A
Prediction of minimal residual disease in pediatric ALL: Evaluation of the predictive potential of the variables from the ALL-BFM 2000 trial
Identification of germline polymorphisms associated with clinical and toxicity phenotypes in childhood acute lymphoblastic leukemia
Müller, I
Long-term infusion of anti-GD2 antibody ch14.18/CHO is active and less toxic in high-risk neuroblastoma patients
Evaluation of clinical responses following long-term infusion of anti-GD2 antibody ch14.18/CHO in high-risk neuroblastoma patients
Müller, J
Targeting the disialoganglioside GD2 in neuroblastoma using a phage display derived oligopeptide
Müller, S
Targeting the disialoganglioside GD2 in neuroblastoma using a phage display derived oligopeptide